Phaseline

Companies › Mediar Therapeutics

Mediar Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Metabolic and endocrine, Immunology, Respiratory; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MTX-463
IgG1 monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1
WISP1Phase 2Idiopathic Pulmonary FibrosisAug 2027
MTX-474
anti-EphrinB2 monoclonal antibody
EFNB2Phase 2Diffuse Cutaneous Systemic SclerosisDec 2028
MTX-439
Anti-SMOC2 monoclonal antibody
SMOC2Phase 1Healthy Adult ParticipantsMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07473323MTX-439Phase 1Healthy Adult ParticipantsMetabolic and endocrineMay 2027
NCT06967805MTX-463Phase 2Idiopathic Pulmonary FibrosisRespiratoryAug 2027
NCT07287670MTX-474Phase 2Diffuse Cutaneous Systemic SclerosisImmunologyDec 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

SMOC2 (1) EFNB2 (1) WISP1 (1)

Companies with the same targets

Vasgene Therapeutics

Companies built like this

Hangzhou Sciwind Biosciences Arcturus Therapeutics Direct Biologics Genrix (Shanghai) Biopharmaceutical Bluefin Biomedicine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.